Operating profit during the period tanked nearly 50 per cent YoY to Rs 723.4 crore. Operating margin in the quarter deteriorated by almost 280 bps from corresponding quarter of previous year to 4.2 per cent.

Syngene International reported healthy performance in the fourth quarter of FY20. Its revenue for the quarter improved 13 per cent YoY to Rs 627.8 crore from Rs 554.7 crore in Q4FY19. This revenue growth was driven by robust performance in discovery and development services

Sonata Software reported its fourth quarter result of FY20 on Monday. Its consolidated revenue for the quarter came in at Rs 928.68 crore, registering decline of 24.92 per cent QoQ

Zydus Cadila today informed the bourses that it has launched Enzalutamide, a highly effective drug for the treatment of prostate cancer, under the brand name ‘Obnyx’ in India. With this launch, the treatment cost of prostate cancer is likely to be reduced by almost 70 per cent

Dr Reddy today informed the bourses that the company has received an establishment inspection report (EIR) from USFDA for API manufacturing plant at Srikakulam, Andhra Pradesh (CTO VI) facility which was audited as on January 29, 202

Dr Reddy's Laboratories informed the bourses today that its subsidiaries have launched Desmopressin Acetate injection USP, 4 mcg/ml single-dose Ampules, a therapeutic equivalent generic version of DDAVP

Lupin informed the bourses about the positive top-line results from its pivotal Phase 3 clinical trial to assess the efficacy and safety of single-dose Solosec (Secnidazole)

KEC International informed the bourses today that it has resumed operations/dispatches at all its five factories in India in a phased manner

Natco Pharma today announced that it has received a final approval for its first supplemental abbreviated new drug application (ANDA) product from US Food & Drug Administration (USFDA)

The domestic rating agency, CRISIL has slashed India's gross domestic product (GDP) estimates to 1.8 per cent for FY21E while, projecting total losses of Rs 10 lakh crore or Rs 7,000 per person owing to lockdowns to control COVID-19 pandemic